Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 16/20 | 0.74 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.74 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533567 | 0.90 | PTGER1 (0.75) | PTGER1PTGER3TBXA2ROGAGAA | |
| SCHEMBL3197367 | 0.89 | PTGER1 (0.74) | PTGER1PTGER3TBXA2R | |
| SCHEMBL3174081 | 0.89 | PTGER1 (0.74) | PTGER1PTGER3TBXA2ROGAGAA | |
| SCHEMBL3181336 | 0.87 | PTGER1 (0.81) | PTGER1PTGER3TBXA2R | |
| SCHEMBL4533394 | 0.86 | PTGER1 (0.80) | PTGER1PTGER3TBXA2R | |
| SCHEMBL3191392 | 0.86 | PTGER1 (0.72) | PTGER1PTGER3TBXA2ROGAGAA | |
| SCHEMBL3184429 | 0.86 | PTGER1 (0.75) | PTGER1PTGER3TBXA2ROGAGAA | |
| SCHEMBL3181320 | 0.79 | PTGER1 (0.74) | PTGER1PTGER3TBXA2R | |
| SCHEMBL4515303 | 0.78 | PTGER1 (0.67) | PTGER1PTGER3TBXA2RNPC1RAB9A | |
| SCHEMBL13533578 | 0.78 | PTGER1 (0.81) | PTGER1PTGER3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016371-A1 | Indole Compounds | IDO1, TPH1, IDO2 | PTGER1 340/4885PTGER3 341/4885TBXA2R 145/4885 |
| US-20090298866-A1 | Indole Compounds | IDO1, TPH1, IDO2 | PTGER1 317/4885PTGER3 361/4885TBXA2R 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.